Pacific Biosciences of California Inc. buy The Goldman Sachs Group, Inc.
Start price
30.06.23
/
50%
€12.81
Target price
30.06.24
€15.60
Performance (%)
-90.29%
End price
01.07.24
€1.24
Summary
This prediction ended on 01.07.24 with a price of €1.24. Massive losses of -90.29% were the result for the BUY prediction by The_Goldman_Sachs_Gr. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Pacific Biosciences of California Inc. | -0.282% | -0.282% | -13.562% | -89.615% |
| iShares Core DAX® | -0.874% | 5.325% | 6.865% | 65.211% |
| iShares Nasdaq 100 | -0.381% | 1.979% | 25.696% | 90.325% |
| iShares Nikkei 225® | -1.676% | 1.952% | 41.443% | 80.623% |
| iShares S&P 500 | -0.655% | 2.069% | 21.405% | 70.737% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Pacific Biosciences of California Inc. diskutieren
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $17.00 price target on the stock.
Ratings data for PACB provided by MarketBeat
In the thread Trading Pacific Biosciences of California Inc.
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten
Stopped prediction by The_Goldman_Sachs_Gr for Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc.
Start price
Target price
Perf. (%)
€3.26
10.04.24
10.04.24
€6.50
10.04.25
10.04.25
-62.31%
11.04.25
11.04.25
